Last updated: 2026-09-07 22:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CytoMed Therapeutics Limited (GDTC) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0,88, with a market capitalisation of $10,19M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,68 to $3,68. This page covers its latest market performance, valuation, price trends and company information.
$10,19M | |
$0,93 | |
$9,25 | |
$0,68 | |
-- | |
16,51K | |
80,37K | |
-- | |
$3,68 | |
$0,68 | |
-- | |
-- |
CytoMed Therapeutics Limited (GDTC) last closed at $0,00 as of 2026-09-04 22:05:00, -- from the previous close of $0,00.
During the latest regular trading session, GDTC traded between $0,68 and $9,25, with a volume of 16,51K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, CytoMed Therapeutics Limited (GDTC) moved from $0,94 to $0,88, representing a decline of 6,42% ($0,06).
The stock traded between $0,76 and $1,00 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 13,43 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6,5%
GDTC is currently trading at $0,88, placing it 6,5% of the way from its 52-week low of $0,68 to its 52-week high of $3,68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Employees | 42 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CytoMed Therapeutics Limited (GDTC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.